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In Brief
Induction of the Ras/ERK signaling
pathway characterizes many tumors and
leads to metabolic changes whose
oncogenic relevance is unclear. Masgras
et al. reveal that ERK1/2 orchestrates a
metabolic switch through
phosphorylation of the mitochondrial
chaperone TRAP1 and the ensuing
inhibition of respiratory complex II that
crucially contributes to neoplastic
growth.
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Mutations in neurofibromin, a RasGTPase-activating
protein, lead to the tumor predisposition syndrome
neurofibromatosis type 1. Here, we report that cells
lacking neurofibromin exhibit enhanced glycolysis
and decreased respiration in a Ras/ERK-dependent
way. In the mitochondrial matrix of neurofibromin-
deficient cells, a fraction of active ERK1/2 associates
with succinate dehydrogenase (SDH) and TRAP1,
a chaperone that promotes the accumulation of the
oncometabolite succinate by inhibiting SDH. ERK1/
2 enhances both formation of this multimeric com-
plex and SDH inhibition. ERK1/2 kinase activity is
favored by the interaction with TRAP1, and TRAP1
is, in turn, phosphorylated in an ERK1/2-dependent
way. TRAP1 silencing or mutagenesis at the serine
residues targeted by ERK1/2 abrogates tumorige-
nicity, a phenotype that is reverted by addition of
a cell-permeable succinate analog. Our findings
reveal that Ras/ERK signaling controls the metabolic
changes orchestrated by TRAP1 that have a key role
in tumor growth and are a promising target for anti-
neoplastic strategies.
INTRODUCTION
Deregulated induction of Ras/ERK signaling stimulates several
biological processes that are crucial for neoplastic growth,
including cellular proliferation, suppression of cell death, and
acquisition of invasive, metastatic, and pro-angiogenic proper-
ties by tumor cells (Dhillon et al., 2007). One mechanism to
enhance signaling through the Ras /ERK transduction pathwayCell
This is an open access article under the CC BY-Nis constituted by inactivation of neurofibromin, a Ras-GTPase-
activating protein (Ras-GAP) (Yap et al., 2014) that inhibits the
proto-oncogene Ras by increasing the intrinsic GTPase activity
of its active, GTP-bound form (Ahearn et al., 2011). Neurofibro-
min is the product of the tumor suppressor gene NF1, whose
loss-of-function mutations cause neurofibromatosis type 1
(NF1), an autosomal-dominant, tumor-predisposing genetic syn-
drome that affects about 1 in 3,000 individuals worldwide (Lin
and Gutmann, 2013). Biallelic inactivating mutations at the NF1
locus induce the formation of a variety of tumor types; among
these are neurofibromas, benign tumors that developwithin peri-
neural sheaths of peripheral nerves and are the hallmark of NF1.
A subset of neurofibromas (called plexiform) grow in peripheral
nerve bundles and can undergo transformation into highly
aggressive sarcomas (Brems et al., 2009). In addition, NF1
patients have an increased risk of developing a variety of other
tumor types, such as glioma, leukemia, pheochromocytoma,
gastrointestinal stromal tumor, rhabdomyosarcoma, and breast
cancer (Lin and Gutmann, 2013). Moreover, NF1 is one of
the most frequently mutated genes in several sporadic malig-
nancies, including lung, breast, ovarian, pancreatic, and prostate
cancer, where NF1 mutations are frequently associated with
resistance to therapy and a poor outcome (reviewed in Ratner
and Miller, 2015).
Even if Ras controls the downstream activation of multiple ef-
fectors (Karnoub and Weinberg, 2008), and neurofibromin is
involved in a number of Ras-independent signaling pathways
(Ratner and Miller, 2015), it is believed that tumorigenesis
caused by lack of neurofibromin specifically requires the deregu-
lated activation of signaling through the Ras/ERK transduction
axis because its inhibition leads to a remarkable anti-neoplastic
effect in several NF1-related tumor models (Barkan et al., 2006;
Jessen et al., 2013; Malone et al., 2014; See et al., 2012).
The Ras/ERK signaling pathway contributes to the metabolic
reprogramming that allows neoplastic cells to thrive under theReports 18, 659–672, January 17, 2017 ª 2017 The Author(s). 659
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conditions of limited oxygen supply that they encounter during
neoplasm accrual (Pylayeva-Gupta et al., 2011; White, 2013).
These metabolic changes are characterized by a partial inhibi-
tion of mitochondrial oxidative phosphorylation (OXPHOS) (Bar-
bosa et al., 2012) as well as by enhanced utilization of glucose
and glutamine for anabolic needs, induction of anti-oxidant
defenses, and anaplerotic supply of the mitochondrial tricar-
boxylic acid (TCA) cycle that is required to maintain both
energy homeostasis and several biosynthetic pathways (Bor-
oughs and DeBerardinis, 2015). The mechanisms by which
oncogenic activation of the Ras/ERK pathway promotes this
rearrangement of metabolic circuitries are only partially under-
stood (White, 2013), and it remains to be established whether
any Ras/ERK-dependent metabolic derangement occurs in tu-
mors related to neurofibromin loss of function and is required
for their progression.
The Ras/ERK pathway has a mitochondrial branch (Zhu et al.,
2003; Poderoso et al., 2008) whose anti-apoptotic functions can
contribute to cell tumorigenicity (Rasola et al., 2010). Many
crucial bioenergetic processes are located in mitochondria or
have mitochondrial components, and mitochondria can play a
promoter role in the tumorigenic process through accumulation
of oncometabolites; i.e., metabolites that contribute to tumori-
genesis via regulation of transcription factors or epigenetic
changes (Yang et al., 2013). One such oncometabolite is succi-
nate; an increase in its intracellular levels causes pseudohypoxia
by stabilizing the hypoxia-inducible transcription factor (HIF-1)
independently of oxygen tension (Selak et al., 2005). The subse-
quent activation of the HIF-1-responsive genes leads to further
metabolic changes and to induction of both angiogenesis and
epithelial-mesenchymal transition (LaGory and Giaccia, 2016;
Semenza, 2013), thus orchestrating progression to malignancy.
It was proposed that Ras/ERK signaling might promote
metabolic changes through HIF-1 activation (Blum et al., 2005;
White, 2013). However, whether the mitochondrial Ras/ERK
axis directly takes part in the mitochondrial metabolic rewiring
associated with neoplastic transformation is not known.
Succinate accumulation can be caused by inactivating muta-
tions in genes encoding succinate dehydrogenase (SDH), an
enzyme that catalyzes both the oxidation of succinate to fuma-
rate and the transfer of electrons to the quinone pool of the
respiratory chain (Cecchini, 2003), therefore being placed at
the crossroad between the TCA cycle and OXPHOS. Such
mutations are found in a panel of tumors that partially overlap
with those associated with NF1; they include paragangliomas,
phaeochromocytomas, gastrointestinal stromal tumors, renal
and thyroid tumors, and neuroblastomas (Bardella et al., 2011;
Hoekstra and Bayley, 2013). We have previously demonstrated
that a pro-neoplastic increase in intracellular succinate levels
can also be prompted by the inhibitory interaction between
SDH and the mitochondrial chaperone TRAP1, which leads to
HIF-1a stabilization and is required for tumor growth (Sciacovelli
et al., 2013). The TRAP1 level has been found to be increased in
several types of tumors (Kang et al., 2007). Furthermore, it was
observed that it is phosphorylated by Ser/Thr kinases (Condelli
et al., 2015; Pridgeon et al., 2007), but it is unknown whether
TRAP1 can be the target of kinase pathways that are aberrantly
activated in tumor cells. Thus it remains unexplored whether and660 Cell Reports 18, 659–672, January 17, 2017how TRAP1 phosphorylation might contribute to the process of
neoplastic growth.
Here we provide a mechanistic connection between deregu-
lated activation of Ras/ERK signaling and the pro-neoplastic
metabolic switch orchestrated by TRAP1. Our observations
demonstrate that active ERK1/2 interacts with TRAP1 and SDH
in mitochondria of neurofibromin-deficient cells and that ERK-
dependent phosphorylation of specific residues on TRAP1 has
a key role in their tumorigenicity.
RESULTS
Lack of Neurofibromin Changes the Bioenergetic
Properties of Cells
We studied themetabolic profile of mouse embryonic fibroblasts
(MEFs) derived from both wild-type mice and syngenic Nf1-
knockout animals (Nf1+/+ and Nf1/ MEFs, respectively) (Sha-
pira et al., 2007; Figure S1A). Nf1/ MEFs had a higher glyco-
lytic activity than their wild-type counterparts, as demonstrated
both by the rise in the extracellular acidification rate following
glucose administration (Figure 1A) and by measurements of
glucose-dependent ATP synthesis (Figure 1B). Moreover, oxy-
gen consumption rate (OCR) experiments revealed that both
basal and coupled respiration as well as maximal and spare res-
piratory capacity were lower in Nf1/ than in Nf1+/+ MEFs (Fig-
ures 1C and 1D; Figure S1B). No differences in mitochondrial
morphology, mass, or membrane potential were detected be-
tween MEFs with or without neurofibromin (Figures S1C and
S2A–S2C). Taken together, these data indicate that lack of neu-
rofibromin per se is sufficient to induce a metabolic shift of cells
toward the Warburg-like phenotype that characterizes many tu-
mor cell types, which is endowed with enhanced glucose usage
and diminished OXPHOS.
ERK1/2 Activity Prompted by Lack of Neurofibromin
Regulates Mitochondrial Bioenergetics
We analyzed the influence of neurofibromin loss on ERK1/2 ac-
tivity in MEFs. As expected, Nf1/ MEFs displayed a constitu-
tively higher level of ERK1/2 phosphorylation than their wild-
type counterparts and underwent a much stronger ERK1/2
induction after growth factor stimulation (Figure 2A). We had pre-
viously observed that, in several cell types, a fraction of ERK1/2
is located in mitochondria and that the activity of this mitochon-
drial ERK1/2 can contribute to the survival of tumor cells
exposed to stress conditions (Masgras et al., 2012; Rasola
et al., 2010). Here we found a fraction of active ERK1/2 in mito-
chondria of cell types that lack neurofibromin, including Nf1/
MEFs (Figure 2B), cells from human plexiform neurofibromas
(Figure 2C), and U87 cells (Figure S1A; Figure 2D) that derive
from a human glioblastoma; i.e., a tumor type frequently associ-
ated with loss of neurofibromin (Cancer Genome Atlas Research
Network, 2008; Hollstein and Cichowski, 2013). We inhibited
ERK1/2 activity in Nf1/ MEFs either through administration of
PD98059, an inhibitor of the upstream kinase MEK (Figure S2D),
or through expression of a dominant-negative MEK1 protein
(MEK1-DN) (Figure S2E). Conversely, we activated ERK1/2 in
Nf1+/+ MEFs by expressing a constitutively active MEK1 protein
(MEK1-CA) (Figure S2E). We found that MEK1 inhibition, which
Figure 1. The Absence of Neurofibromin Changes the Bioenergetics of MEFs
(A) Representative measurements of the extracellular acidification rate (ECAR) performed on MEF monolayers. Subsequent additions of glucose, the ATP
synthase inhibitor oligomycin, and the hexokinase inhibitor 2-deoxy-glucose (2-DG) were carried out where indicated.
(B) ATP levels were measured in Nf1+/+ and Nf1/ MEFs kept under standard culture conditions (bars on the left) or undergoing 2-hr glucose depletion with or
without the hexokinase inhibitor 5-thio-glucose (5-TG).
(C and D) Representative traces (C) and quantification (D) of the oxygen consumption rate (OCR) in MEFs. Subsequent additions of oligomycin, which allows
determination of respiration coupled to ATP synthesis, of the proton uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), which indicates
the maximal and the spare respiratory capacity, and of the respiratory complex I and III inhibitors rotenone and antimycin A, respectively, were carried out as
indicated.
Data are reported as mean ± SD values (nR 3); asterisks indicate significant differences (***p < 0.01, *p < 0.05; Student’s t test analysis). See also Figures S1
and S2.did not alter, per se, either the mass or membrane potential of
mitochondria (Figures S2A–S2C), increased the OCR both in
Nf1/ MEFs (Figures 2E and 2F; Figure S2F) and in U87 glio-
blastoma cells (Figures 2G and 2H). In the mirror experiment,
ERK1/2 activation by MEK1-CA expression markedly decreased
the OCR of Nf1+/+ MEFs, making them reach a respiratory profile
similar to that of MEFs lacking neurofibromin (Figures 2E and 2F;
Figure S2F).
These results indicate that deregulated activation of the
Ras/ERK signaling pathway in neurofibromin-deficient cells isresponsible for a metabolic rearrangement characterized by a
decrease in mitochondrial OXPHOS.
Mitochondrial ERK1/2 Inhibits SDH following Interaction
with TRAP1
We then asked whether ERK1/2 could alter the mitochondrial
bioenergetics of neurofibromin-deficient cells by directly inter-
acting with any OXPHOS complex. We found that ERK1/2 asso-
ciated both with the respiratory complex II, also known as SDH,
and with the mitochondrial chaperone TRAP1 in Nf1/ MEFsCell Reports 18, 659–672, January 17, 2017 661
Figure 2. Active ERK1/2 Is in Mitochondria of Cells Lacking Neurofibromin and Regulates Their Bioenergetic Features
(A) Changes in ERK1/2 phosphorylation following 2-hr serum depletion of Nf1+/+ and Nf1/MEFs and subsequent exposure to PDGF (10 ng/ml, 10min); calnexin
was used as a loading control.
(B–D) Expression of active, phosphorylated ERK1/2 was assessed in the cytosolic andmitochondrial fractions of MEFs (B), in mitochondria from a representative
plexiform neurofibroma (C), and in the cytosolic and mitochondrial fractions of U87 human glioblastoma cells (D). Cyclophilin D (CyP-D), TRAP1, and SDH
subunits A (SDHA) and B (SDHB) were used as mitochondrial markers; calnexin was used as an indicator of the presence of non-mitochondrial proteins.
(E–H) Representative traces (E and G) and quantification (F and H) of the OCR are shown as in Figure 1. In (E) and (F), experiments were conducted on Nf1+/+ and
Nf1/ MEFs and in (G) and (H) on U87 glioblastoma cells; where indicated, cells expressed the constitutively active or the dominant-negative MEK1 protein
(MEK1-CA and MEK1-DN, respectively).
Data are reported as mean ± SD values (nR 3); asterisks indicate significant differences (***p < 0.01, *p < 0.05; Student’s t test analysis). See also Figures S1
and S2.
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(Figures 3A–3C; Figures S3A–S3B); no interaction could be de-
tected between ERK1/2 and any other OXPHOS component
(data not shown). In cells lacking neurofibromin, the phosphory-
lated, active form of ERK1/2 was part of this multimeric complex,
whereas it was barely detectable in Nf1+/+ MEFs, in which the
interaction among these proteins was weaker (Figure 3C; Fig-
ure S3A). Moreover, in vitro phosphorylation shifted TRAP1,
SDH, and ERK1/2 to high-molecular-weight complexes in mito-
chondria of Nf1/ MEFs, whereas phosphatase treatment
enhanced the dissociation of such multimers (Figure 3A). These
data, together with the observation that inhibition of phosphory-
lation does not affect the interaction between TRAP1 and either
SDH or ERK1/2 (Figure 3B; Figure S3B), suggest that a phos-
phorylation-dependent process is specifically involved in the for-
mation of large complexes among these proteins.
The succinate:coenzyme Q reductase (SQR) enzymatic activ-
ity of SDH was lower in Nf1/ than in Nf1+/+ MEFs (Figure 3D).
We also found that SQR activity inversely correlated with
ERK1/2 induction in Nf1/ MEFs; it increased under starvation
conditions, where ERK1/2 was completely inhibited, whereas
the subsequent PDGF treatment, which strongly activated
ERK1/2, lowered SQR activity back to its basal level (compare
Figure 3E with Figure 2A for ERK1/2 modulation). These data
indicated that ERK1/2 activation could downregulate SDH activ-
ity and were corroborated by the observation that expression of
a kinase-dead ERK2 enzyme increased the SQR activity of SDH
in neurofibromin-deficient cells (Figure 3F), whereasNf1+/+MEFs
expressing a MEK1-CA protein showed SQR inhibition (Fig-
ure 3G). Modulation of SDH activity by the Ras/ERK pathway
was independent of changes in SDH protein levels; these were
not affected either by the absence of neurofibromin or by inhibi-
tion of the Ras/ERK pathway (Figure S2B). Moreover, TRAP1
expression levels were similar in Nf1+/+ and Nf1/ MEFs (Fig-
ure S3B). Like in Nf1/ MEFs, we found that active ERK1/2,
TRAP1, and SDH also interacted in human U87 glioblastoma
cells (Figure 3H), and expression of a kinase-dead ERK2 protein
that partially localized in mitochondria did not change the protein
levels of SDH (Figure S3D) but increased its SQR enzymatic ac-
tivity (Figure 3I).
TRAP1 Is Phosphorylated in an ERK-Dependent Way
To further elucidate the functional meaning of the interaction
between mitochondrial ERK1/2 and TRAP1, we investigated
whether TRAP1 was an ERK1/2 phosphorylation target. We
found that TRAP1 was Ser/Thr-phosphorylated after treatment
with platelet-derived growth factor (PDGF) or expression of
wild-type ERK and that TRAP1 phosphorylation was decreased
both under starvation and upon expression of the kinase-dead
ERK2 protein (Figures 4A and 4B). It was shown that the chap-
erone activity of TRAP1 is enhanced after heat shock up to
55C (Leskovar et al., 2008 and unpublished data). We reasoned
that, under these conditions, TRAP1 interactors and TRAP1-
dependent regulatory events would be selectively preserved,
whereas the conformation and activity of non-chaperoned
mitochondrial proteins would be lost. Accordingly, after a short
heat shock, both TRAP1 and ERK1/2 were maintained in the sol-
uble fraction, whereas mitochondrial Akt was not detectable
anymore (Figure S4A). Notably, after the heat shock we coulddetect both active ERK1/2 (Figures S4A and S4B) and phosphor-
ylated TRAP1 (Figures 4C and 4D; Figures S4A and S4B). TRAP1
phosphorylation was markedly decreased both by the wide-
spectrum kinase inhibitor staurosporine and in the presence of
a kinase-dead form of ERK2 (Figures 4C and 4D; Figure S4B).
These data strongly support the hypothesis that TRAP1 is
phosphorylated in an ERK1/2-dependent way. Hence, to deter-
mine ERK1/2 target residues on TRAP1, we crossed data
obtained with the platforms Prediction of PK-Specific Phosphor-
ylation Site (http://ppsp.biocuckoo.org/) and Phospho Site
Plus (http://www.phosphosite.org/), finding Ser226, Ser511,
and Ser568 to be potential ERK phosphorylation sites on human
TRAP1. We then measured the solvent accessibility of these
sites using all-atom explicit solvent molecular dynamics (MD)
simulation either for the apo and ADP-bound form of the chap-
erone to account for the fluctuations around the native state of
the protein. We selected the only full-length and dimeric 3D
structure available so far in the PDB for TRAP1, that of Danio
rerio (Lavery et al., 2014), in which Ser511 and Ser568 are re-
placed by Ser526 and Ser582, respectively, whereas Ser226 is
substituted by Ala241. The most accessible phospho site and,
thus, available for a kinase independently of the cofactor-bound
state of the protein in the simulations of the closed state of the
protein was Ser582 (Ser568 in Figure 4E and Table S1). Further-
more, Ser582 was the only site whose phosphorylation was
not expected to destabilize the protein because the DDG be-
tween the folded and unfolded state upon phosphorylation
was 0.77 kcal/mol, whereas phosphorylation at the other two
sites induced a destabilizing DDG of more than 3.8 kcal/mol in
the closed state of the chaperone, in agreement with the fact
that these sites are partially buried in the closed structure. How-
ever, TRAP1 has been suggested to undergo large conforma-
tional changes during the catalytic cycle, converting from closed
states (as the ones simulated here) to open states, as also
observed in other chaperones (Krukenberg et al., 2011; Lavery
et al., 2014). The destabilization of the closed state predicted
by the DDG calculations suggested that phosphorylation at
Ser526 was favored in the open state. We thus built a model of
the open conformation of TRAP1 in its apo state based on the
structure of E.coli HSP90 (PDB: 2IOQ; Shiau et al., 2006), and
the location of Ser511 (Ser526 in Figure 4F) suggested that its
accessibility could be modulated by opening/closing motions
of the chaperone, increasing more than 10-fold in the model of
the open state.
These predictions were confirmed by amarked decrease in the
phosphorylation of TRAP1 followingSer-to-Alamutagenesis both
at the 511 and at the 568 residue (Figure 4G). Interestingly, both
mutants markedly decreased the capability to form high molecu-
lar complexeswithERK1/2 andSDH (compareFigure 4HandFig-
ure S4C with Figure 3A). We also observed that inhibition of the
TRAP1 chaperone cycle with the use of 17-(Allylamino)geldana-
mycin (17-AAG) dissociates it fromERK1/2, whereas the complex
wasmaintained in thepresenceof the kinase inhibitor staurospor-
ine (Figures 4I and 3B). The ERK capability to phosphorylate
TRAP1wasnot affectedby 17-AAGwhen the latterwasaddedaf-
ter heating (Figures 4I; Figure S4B), but treatment with 17-AAG
before the heat shock induced the dissociation of TRAP1 from
ERK1/2, thus allowing ERK1/2 degradation (Figure 4I).Cell Reports 18, 659–672, January 17, 2017 663
Figure 3. ERK1/2 Interacts with TRAP1 and SDH in Mitochondria of Cells Lacking Neurofibromin and Downmodulates Their SQR Enzymatic
Activity
(A) Gel filtration chromatography analysis of TRAP1, ERK1/2, and SDHA distribution in Nf1/MEFmitochondria. Mitochondrial extracts were left untreated (top),
exposed to lambda phosphatase (lPPase, center), or underwent an in vitro kinase assay (IVKA, bottom).
(legend continued on next page)
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Taken together, these observations indicate that TRAP1 phos-
phorylation occurs in neurofibromin-deficient cells upon ERK
activation and that, in turn, TRAP1 acts as a chaperone to main-
tain ERK1/2 activity in mitochondria. It was therefore pivotal to
understand whether this multimeric complex affected the onco-
genic potential of cells lacking neurofibromin.
ERK-Dependent Phosphorylation of TRAP1 Is Required
for Its Oncogenic Activity through Inhibition of SDH and
Prolyl Hydroxylases
It was shown that activation of Ras/ERK signaling is mandatory
for the growth of NF1-related tumors (Barkan et al., 2006; Jessen
et al., 2013;Malone et al., 2014; See et al., 2012) even though any
characterization of their metabolic features is missing. We found
that lack of neurofibromin conferred tumorigenicity toMEFs both
in vitro and in vivo (Figures 5A–5C). The oncogenic importance of
the Ras/ERK transduction pathway in this model was highlighted
by the observation that MEK inhibition blunted the ability of
Nf1/ MEFs to grow in soft agar (Figures 5A and 5B) without
affecting cell viability per se (Figure S5A), whereas ERK1/2 in-
duction by expression of MEK1-CAwas sufficient to elicit forma-
tion of colonies by Nf1+/+ MEFs (Figure 5B). Similarly, the tumor-
igenic properties of U87 glioblastoma cells were inhibited by
blocking the Ras/ERK transduction pathway (Figure S5B). Tu-
mors formed by Nf1/ MEFs following injection in nude mice
were exclusively formed by cells lacking neurofibromin (Fig-
ure 5C) that were endowed with the presence of TRAP1 and
an active ERK1/2 in mitochondria (Figure 5D) and with induction
of both HIF-1a and of the lactate transporter MCT4 (Figure 5E), a
HIF-1a transcriptional target that is a marker of a metabolic shift
toward a Warburg phenotype.
We then assessed the role of TRAP1 in the tumorigenicity of
cells lacking neurofibromin. In accord with our previous results
in other cell models (Sciacovelli et al., 2013), TRAP1 silencing
(Figures S6A–S6C) increased cell respiratory capacity (Fig-
ure S6D) and abrogated both the ability of cells to form colonies
in soft agar (Figure 6A; Figure S6E) and in vivo tumor growth
(Figure 6B).
We had previously shown that TRAP1 prompts a succinate-
dependent inhibition of prolyl hydroxylase (PHD) that is pro-
neoplastic by hampering the proteasomal degradation of
HIF-1a (Sciacovelli et al., 2013). Accordingly, the tumorigenicity
of TRAP1-silenced cells lacking neurofibromin was restored
by the supply of a cell-permeable succinate analog (dimethyl
succinate, DMS) (Figure 6C; Figures S6F and S6G), which in-
hibits PHD. The capability to form colonies after DMS treatment(B) TRAP1 immunoprecipitation from Nf1/ MEF mitochondria; where indicate
osporine (STS, 5 mM, 15 min).
(C) Blue native gel electrophoresis performed on mitochondria isolated from Nf1+
run on an SDS-PAGE, and probed with anti- SDHB, anti-phospho-ERK1/2, and
(D–G) Analysis of the SQR enzymatic activity of SDH in Nf1+/+ and Nf1/MEFs (D)
with PDGF (10 ng/ml) (E) or that expressed the dominant-negative mutant K52R
(H) Crosslinking experiments on mitochondria from U87 glioblastoma cells. TRA
DTBP; samples were then loaded in parallel on separate lanes of a SDS-PAGE. In
bottom part, crosslinked immunoprecipitates were cleaved by reducing DTBP w
(I) Analysis of the SQR enzymatic activity of SDH in U87 glioblastoma cells either
mutant K52R ERK2.
Data are reported as mean ± SD values (nR 3); asterisks indicate significant difwas abrogated by a cell-permeable form of a-ketoglutarate
(1-trifluoromethylbenzyl-a-ketoglutarate, TaKG), which reverses
HIF-1a stabilization by restoring PHD enzymatic activity (Fig-
ure 6C; Figure S6G).
We also found that ERK-dependent phosphorylation of
TRAP1 was required for SDH inhibition and for neoplastic
growth. Indeed, we observed that, following ERK activation by
PDGF treatment, TRAP1 knockout cells expressing the S568A
TRAP1 mutant inhibited the SQR enzymatic activity of SDH
less than cells expressing wild-type TRAP1 (Figure 6D) and
that tumorigenicity was inhibited or delayed in cells expressing
TRAP1 mutants (Figures 6E and 6F). Finally, we detected a
high level of expression of TRAP1, HIF-1a, and PKM2, a HIF-
1a transcriptional target that contributes to the metabolic switch
toward an aerobic glycolysis phenotype (Li et al., 2014), in plex-
iform neurofibroma samples that are characterized by strong
ERK1/2 activation (Figure 6G). These data highlight the onco-
genic role played by a mitochondrial signaling axis involving
ERK1/2, TRAP1, and SDH.
DISCUSSION
Activating mutations of the proto-oncogene Ras (Karnoub and
Weinberg, 2008; Pylayeva-Gupta et al., 2011) and of its down-
stream effector Raf (Lavoie and Therrien, 2015) as well as homo-
zygous loss-of-function mutations of the Ras-GAP neurofibro-
min (Ratner and Miller, 2015) are observed in a high proportion
of tumor types, where deregulated activation of Ras/ERK
signaling crucially contributes to neoplastic growth. Intensive ef-
forts have been devoted to dissecting the changes elicited in a
variety of molecular circuitries by hyperactivation of this trans-
duction pathway. Nonetheless, an in-depth dissection of the
mechanisms by which the Ras/ERK pathway takes part in the
metabolic changes of tumor cells (White, 2013) is still missing,
and the importance of such changes for tumor growth is unclear.
Moreover, very little is known about the role played by the mito-
chondrial branch of Ras/ERK signaling in the process of
neoplastic progression. Key findings of the present work are
the identification of a fraction of active ERK1/2 inside the mito-
chondria of cells lacking neurofibromin and the demonstration
that this mitochondrial ERK1/2 prompts a pro-neoplastic meta-
bolic switch upon its interaction with the mitochondrial chap-
erone TRAP1.
We had previously shown (Rasola et al., 2010) that, in several
tumor cell types, themitochondrial fraction of ERK1/2 inhibits the
permeability transition pore, a channel whose opening commitsd, mitochondria were treated with the wide-spectrum kinase inhibitor staur-
/+ and Nf1/ MEFs. Bands corresponding to complex II (CII or SDH) were cut,
anti-TRAP1 antibodies.
, in Nf1/MEFs that underwent serum starvation for 2 hr andwere then treated
ERK2 (F), and in Nf1+/+ MEFs expressing MEK1-CA (G).
P1 was immunoprecipitated after mitochondrial treatment with the crosslinker
the top part of the Figure, red arrowheads highlight crosslinked proteins; in the
ith DTT, and separated proteins are indicated by blue arrowheads.
transduced with a scramble vector (SCR) or expressing the dominant-negative
ferences (***p < 0.01, *p < 0.05; Student’s t test analysis). See also Figure S3.
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cells to death (Rasola and Bernardi, 2007), by regulating a
signaling axis that involves GSK3 and the chaperone cyclophilin
D. Hence, mitochondrial ERK could crucially contribute to the
ability of escaping cell death that characterizes malignant cells.
Our present data indicate that mitochondrial ERK plays another
oncogenic role by regulating the bioenergetic changes occurring
during neoplastic growth. A crucial pro-neoplastic metabolic
adaptation is pseudohypoxia; i.e., oxygen-independent activa-
tion of the transcription programs mastered by HIF-1 that
promote epithelial-to-mesenchymal transition, angiogenesis,
and metabolic, Warburg-like adaptations (LaGory and Giaccia,
2016; Semenza, 2013), thus equipping cells to face shortages
of oxygen or nutrients. Subsets of pseudohypoxic cells might
be selected to advance through the early phases of neoplastic
progression or to switch to a malignant phenotype under the
pressure of local environmental factors, such as increasing dis-
tance from the microvessel network. It is conceivable that these
adaptive changes must be flexibly regulated and that this may
occur, at least in part, at a post-transcriptional level. This type
of adaptation could be particularly important in shaping the
oncogenic properties of tumors like neurofibromas, whose pro-
gression and clinical course result from complex heterotypic in-
teractions among different cell types (Lin and Gutmann, 2013;
Ratner andMiller, 2015) that go beyond the genotype/phenotype
correlation with mutations causing loss of neurofibromin.
The mitochondrial chaperone TRAP1 plays a pivotal role
in establishing the pseudohypoxic condition discussed above.
TRAP1 inhibits SDH activity, and the resulting increase in intra-
cellular succinate levels inhibits the prolyl hydroxylases respon-
sible for dispatching HIF-1a to the proteasome for degradation
(Sciacovelli et al., 2013). Here we connect this oncogenic func-
tion of TRAP1 to activation of Ras/ERK signaling. We have
demonstrated that active ERK1/2 directly interacts with TRAP1
and SDH in mitochondria of cells, where this signaling axis is
aberrantly activated by the absence of neurofibromin. TRAP1Figure 4. TRAP1 is Phosphorylated in an ERK-Dependent Way
(A) Western immunoblot showing Ser/Thr phosphorylation of a band co-local
phosphorylation is inhibited in cells expressing the dominant-negative mutant K5
(B) Isoelectrofocusing analysis performed after TRAP1 immunoprecipitation from
was around 7.0 when ERK1/2 was inhibited by serum depletion or by expression o
PPase. The TRAP1 IEP shifted to 6.6 when ERK1/2 was activated by cell treatm
Orange arrowheads highlight TRAP1 spots.
(C) Autoradiography following an in vitro kinase assay performed on the TRAP1
(D) Autoradiography and western immunoblot analyses of mitochondria from U8
negativemutant FLAG-K52R ERK2. As reported, in each lane pair were loaded eith
ERK1/2.
(E) Location of the predicted phospho sites on the 3D structure of TRAP1 fromDan
to red according to the average solvent accessibility calculated in the molecu
respectively.
(F) Predicted location of S526 in the apo structure of TRAP1 from Danio rerio.
(G) Autoradiography performed on mitochondria from Nf1/ MEFs transduced w
S568A human TRAP1 cDNA after endogenous TRAP1 had been knocked out by a
highlighted by the orange arrowhead.
(H) Gel filtration chromatography analysis of TRAP1, ERK1/2, and SDHA distrib
Mitochondrial extracts were either left untreated (top) or underwent an IVKA (bot
(I)Western immunoblot analysis of input and ERK1/2 immunoprecipitates frommit
3min and then exposed to 17-AAG for 15min. Right: 17-AAGwas added before h
carried out on the corresponding samples reported in the blot.
See also Figure S4.is likely to play an important chaperone function in the mainte-
nance of this molecular platform because it is able to maintain
the binding with both ERK1/2 and SDHA even under stress
conditions such as heat shock and to keep ERK1/2 enzymati-
cally active. Furthermore, the association between TRAP1 and
ERK1/2 is disrupted following blockade of the TRAP1 chaperone
cycle. It is intriguing that, on one hand, TRAP1 acts as a chap-
erone on ERK1/2 and, on the other hand, ERK1/2 phosphory-
lates TRAP1. By a molecular dynamics simulation we have iden-
tified two putative TRAP1 residues that are targeted by ERK,
Ser511 and Ser568, which have then been confirmed as bona
fide ERK phosphorylation targets by in vitro kinase assays. For-
mation of this mitochondrial multimeric complex is increased
following ERK1/2 activation, as shown by co-immunoprecipita-
tion, blue native (BN)-PAGE, and gel filtration experiments, and
directly influences the bioenergetic features of tumor cells.
Indeed, we found that the SQR enzymatic activity of SDH is
decreased in an ERK1/2-dependent way and that ERK-depen-
dent phosphorylation of TRAP1 is required for SDH inhibition.
Moreover, our findings that both ERK1/2 inhibition and TRAP1
ablation increase the oxygen consumption rate and coupled
respiration and respiratory reserve, moving cell metabolism
away from aWarburg-like phenotype, further highlight the bioen-
ergetic importance of this regulatory mechanism.
The interaction among ERK1/2, TRAP1, and SDH has crucial
consequences for cell tumorigenicity. Immortalized MEFs
constitute an ideal model to analyze oncogenic effects down-
stream of hyperactivation of Ras/ERK signaling because its in-
duction is sufficient to confer cell transformation ability (Hahn
et al., 1999). Accordingly, we observe that ERK1/2 activation,
either following neurofibromin loss or expression of a constitu-
tively active MEK1, is mandatory for MEF transformation,
which is totally lost following ERK1/2 inhibition. Notably, in this
cell model, TRAP1 ablation completely abrogates neoplastic
growth. In accord with our previous model of a TRAP1-drivenizing with immunoprecipitated TRAP1 from U87 glioblastoma cells. Ser/Thr
2R ERK2.
mitochondria of U87 glioblastoma cells. The isoelectric point (IEP) of TRAP1
f the dominant-negativemutant K52R ERK2 or when samples were treatedwith
ent with PDGF, as shown in Figure 2A, or after expression of wild-type ERK2.
immunoprecipitation shown in Figure 3B.
7 glioblastoma cells expressing either FLAG-wild-type ERK2 or the dominant-
er 10 or 20 mg of mitochondrial lysate. Orange arrowheads indicate TRAP1 and
io rerio. The accessible surface of each of the three sites is colored from yellow
lar dynamics simulations. The two monomers are shown in green and cyan,
ith an empty vector (EV) or with constructs expressing wild-type or S511A or
CRISPR/Cas9 approach. Phosphorylation of a band corresponding to TRAP1 is
ution in mitochondria of Nf1/ MEFs expressing the S511A TRAP1 mutant.
tom).
ochondria of Nf1/MEFs. Left: mitochondrial sampleswere heated at 55C for
eating. Bar graphs indicate ERK1/2 activity measured in an in vitro kinase assay
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Figure 5. Activation of ERK1/2 Signaling Is Mandatory for the Tumorigenicity of Cells Lacking Neurofibromin
(A and B) Modulation of soft agar growth in Nf1+/+ and Nf1/MEFs by theMEK inhibitor PD98059 (A) and by expression of MEK1-CA andMEK1-DN proteins (B).
(C) Kinetics of tumor growth in SCIDmice after injection of Nf1+/+ and Nf1/MEFs; a representative tumor fromNf1/MEFs is shown as an inset. Cells extracted
from tumor samples lack neurofibromin expression.
(D) Western immunoblot of tumor samples obtained following injection of Nf1/ MEFs in nude mice showing the mitochondrial expression of TRAP1, active
ERK1/2, and SDH. Caspase-3 was used as a cytosolic marker.
(E) Immunohistochemical inspections of serial sections of Nf1/ MEF tumors reveal the presence and co-localization of TRAP1, HIF-1a, and the HIF-1a
metabolic target MCT4.
In (A)–(C), data are reported as mean ± SD values (nR 3); asterisks indicate significant differences (***p < 0.01, Student’s t test analysis). See also Figures S5
and S6.pseudohypoxic signaling axis, TRAP1-bearing xenograft tumors
display HIF-1a stabilization, and succinate can reinstate the
tumorigenicity of cells lacking TRAP1, but not when prolyl hy-
droxylases are activated by a-ketoglutarate. In addition, here
we also observe that cells expressing TRAP1 mutants that
cannot be phosphorylated in an ERK-dependent way become
unable to undergo neoplastic growth. This result highlights the
oncogenic importance of the mitochondrial interaction between668 Cell Reports 18, 659–672, January 17, 2017ERK1/2 and TRAP1 and indicates that TRAP1 is a pro-neoplastic
metabolic effector of Ras/ERK signaling.
It must be underlined here that we also find TRAP1 and active
ERK1/2 in mitochondria of other neoplastic cells endowed with
loss of neurofibromin, such as neurofibroma samples, where
we also observe induction of HIF1a and of its downstreammeta-
bolic effectors, or U87 human glioblastoma cells, where TRAP1
ablation has the same anti-neoplastic effect observed in MEFs.
Figure 6. TRAP1 Is Required for the Tumorigenicity of Cells Lacking Neurofibromin through ERK-Dependent Inhibition of SDH
(A) Inhibition of soft agar growth in Nf1/ MEFs following ablation of TRAP1 expression through RNAi (shTRAP1 cells).
(B) Kinetics of tumor growth in SCID mice after injection of Nf1/ MEFs with or without TRAP1.
(legend continued on next page)
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Hence, this study suggests that TRAP1 regulation by mitochon-
drial ERK1/2 is amajor regulatory pathway for the oncogenic role
of the chaperone and that it could be a general mechanism of
rapid and flexible metabolic tuning shared by cells characterized
by oncogenic activation of Ras/ERK signaling. This possibility is
strengthened by recent observations indicating that TRAP1 is
regulated in several ways at the post-translational level (Condelli
et al., 2015; Kowalik et al., 2016; Rizza et al., 2016). These subtle
and complex mechanisms of modulation of TRAP1 activity,
together with its changes in expression depending on the tumor
type and stage, might also explain the reported contrasting
effects of the chaperone on the neoplastic process (Yoshida
et al., 2013; for a thorough discussion see Rasola et al., 2014).
Moreover, our data do not exclude the possibility that TRAP1
also contributes to the tumorigenicity of cells by mechanisms
other than pseudohypoxic stabilization of HIF1a and, perhaps,
different from bioenergetic changes because it is plausible that
TRAP1 interacts with multiple mitochondrial clients.
Our results identify a mechanistic connection between de-
regulated Ras/ERK signaling and the pro-neoplastic metabolic
switch orchestrated by TRAP1, demonstrating that active
ERK1/2 interacts with TRAP1 and SDH in the mitochondria of
neurofibromin-deficient cells and that ERK-dependent phos-
phorylation of specific residues on TRAP1 has a key oncogenic
role. It is important to note that, in several tumor types, TRAP1
expression is strongly induced (Kang et al., 2007), sometimes
from the very early stages of neoplastic growth (Kowalik et al.,
2016), making it a suitable and promising target for the develop-
ment of novel anti-tumor strategies that could have few negative
effects on non-transformed tissues.
EXPERIMENTAL PROCEDURES
Detailedmethods can be found in the Supplemental Experimental Procedures.
Cells and Tissue Samples
Experiments were performed onwild-type andNf1 knockoutMEFs and human
U87 glioblastoma cells. TRAP1 expression was knocked down by stable trans-
fection with short hairpin RNAs (shRNAs) or knocked out with a CRISPR/Cas9
approach. pBABE vectors were used for expression of CA (S217E/S221E) and
DN (S217A)MEK1; pFLAG vectors were used for expression of thewild-type or
kinase-dead (K52R) ERK2mutant. TheQuikChange site-directedmutagenesis
kit (Stratagene) was used to generate TRAP1 mutants. Tissue samples from
human plexiform neurofibromas were obtained from patients diagnosed with
NF1 during surgical cancer removal after express written informed consent.
Immunohistochemical analysis was performed in accordance with the decla-
ration of Helsinki and following the regulation of the Padova Hospital Ethical
Committee.(C) Modulation of soft agar growth in Nf1/ MEFs with or without TRAP1 by th
esterified form of a-ketoglutarate (TaKG, 1 mM).
(D) Analysis of the SQR enzymatic activity of SDH in Nf1/ MEFs where the endo
either wild-type ormutant (S568A) human TRAP1 were re-expressed (Figure 4G). S
and that were then treated with PDGF (10 ng/ml, right).
(E) Inhibition of colony growth in Matrigel in Nf1/ MEFs where TRAP1 had been
expressed. Expression of wild-type human TRAP1 restored colony growth.
(F) Kinetics of in vivo tumor growth of Nf1/ MEFs expressing either the wild-ty
(G) Immunohistochemical inspections of serial sections of a representative huma
ERK1/2, TRAP1, HIF-1a, and the HIF-1a metabolic target PKM2.
Data are reported as mean ± SD values (n R 3); asterisks indicate significant d
expressed in cubic millimeters. See also Figure S6.
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Cell tumorigenicity was assessed both in vitro, with assays of growth in soft
agar or in Matrigel, and in vivo following cell injection in severe combined im-
munodeficiency (SCID) mice.
Cytofluorimetric Analyses
Cytofluorimetric analyses were utilized to measure cell death with the use of
Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide probes as
well as mitochondrial mass with the use of nonyl acridine orange and mito-
chondrial membrane potential with the tetramethylrhodamine methyl ester
(TMRM) dye.
Mitochondrion Purification
Mitochondria were isolated through sequential centrifugations after mechani-
cal cell disruption. To eliminate cytosolic contaminants, isolated mitochondria
were partially digested with different concentrations of trypsin.
Biochemical Analyses
Western immunoblot and immunoprecipitation experiments were performed
following standard techniques. BN-PAGE experiments were carried out on
mitochondria to isolate electron transport chain (ETC) complexes. After a first
electrophoresis under non-denaturing conditions, bands were visualized with
Coomassie blue staining, cut, and run on SDS-PAGE for protein identification
bywestern immunoblot. Crosslinking assays were performed on isolatedmito-
chondria incubated with the membrane-permeable, homobifunctional reagent
dimethyl 3,30-dithiobis-propionimidate (DTBP) prior to immunoprecipitation.
Isoelectrofocusing experiments were conducted on mitochondria after
TRAP1 immunoprecipitation. First-dimension electrophoreses were carried
out using linear pH gradient strips and were followed by SDS-PAGE and west-
ern immunoblot. Gel filtration chromatographies were carried out following
standard techniques by using fast protein liquid chromatography (FPLC)
Superdex S200 columns. In vitro kinase assays were carried out by labeling
mitochondria with [g-32P]-ATP. Phosphate incorporation was assessed by
autoradiography.
Measurement of SQR Activity of SDH
The SQR activity of SDH was measured with classical spectrophotometric
approaches on cell or mitochondrial lysates. Each measurement of respiratory
chain (RC) complex activity was normalized for protein amount and for citrate
synthase activity.
Measurements of OCR and ECAR
In vivo respiration and the glycolytic pathway were followed in a kinetic mode
bymeasuring the OCR and extracellular acidification rate (ECAR) of cell mono-
layers with an extracellular flux analyzer (Seahorse Biosciences).
Immunohistochemical Analyses
Immunohistochemical inspections were performed on serial sections of
paraffin-embedded tumor samples following standard procedures.
Intracellular ATP Determination
Intracellular ATP was quantified by the luciferin/luciferase method. Cells were
kept for 2 hr under the different experimental conditions.e cell-permeable succinate analog DMS (0.5 mM) and by the cell-permeable
genous TRAP1 had been knocked out through a CRISPR/Cas9 approach and
QR activity was assessed in cells that underwent serum starvation for 2 hr (left)
knocked out as in (D) and human TRAP1 mutants (S511A or S568A) were re-
pe TRAP1 or TRAP1 mutants S511A or S568A.
n plexiform neurofibroma reveal the presence and co-localization of phospho-
ifferences (***p < 0.01, *p < 0.05; Student’s t test analysis). Tumor volume is
Molecular Dynamics Simulations
Molecular dynamics simulations were performed using GROMACS 4.6
(http://www.gromacs.org). The X-ray structure of TRAP1 was solved in the
presence of the ATP analog adenylyl-imidodiphosphate (AMP-PNP), which
was removed for modeling the apo variant. The models of the ADP and
ATP-bound states of TRAP1 were generated using Modeler, whereas DDG
calculations were carried out with the FoldX suite (http://foldxsuite.crg.eu/).
Statistical Analysis
Student’s t test was used to compare pairs of data groups. ANOVA followed by
Bonferroni post hoc test was used for multiple comparisons. In all figures, bar
graphs report mean ± SD values (nR 3); *p < 0.05, ***p < 0.01.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.12.056.
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